BSE Live
Jan 23, 16:01Prev. Close
458.10
Open Price
458.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 23, 15:48Prev. Close
458.00
Open Price
460.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
440.25 (137)
| Profit & Loss account of Thyrocare Technologies (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 171.74 | 146.28 | 130.75 | 106.59 | 76.07 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 171.74 | 146.28 | 130.75 | 106.59 | 76.07 | |
| Total Operating Revenues | 180.08 | 149.98 | 134.26 | 109.08 | 77.87 | |
| Other Income | 6.97 | 6.58 | 5.73 | 5.11 | 3.34 | |
| Total Revenue | 187.05 | 156.56 | 139.99 | 114.19 | 81.21 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 48.66 | 36.21 | 29.67 | 23.80 | 18.73 | |
| Purchase Of Stock-In Trade | 6.67 | 6.40 | 5.96 | 4.91 | 5.23 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -0.10 | -0.10 | -0.04 | 0.36 | -0.52 | |
| Employee Benefit Expenses | 17.26 | 12.09 | 9.03 | 7.12 | 5.31 | |
| Finance Costs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation And Amortisation Expenses | 10.71 | 6.36 | 3.32 | 2.09 | 1.31 | |
| Other Expenses | 34.31 | 26.70 | 26.18 | 23.89 | 13.53 | |
| Total Expenses | 117.50 | 87.66 | 74.11 | 62.17 | 43.58 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 69.54 | 68.90 | 65.87 | 52.01 | 37.63 | |
| Exceptional Items | 2.08 | 0.00 | 12.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 71.62 | 68.90 | 77.87 | 52.01 | 37.63 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 25.00 | 22.20 | 20.71 | 17.22 | 13.29 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -1.83 | 0.54 | 0.34 | -0.15 | -0.49 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 23.17 | 22.74 | 21.06 | 17.07 | 12.80 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 48.45 | 46.16 | 56.82 | 34.94 | 24.83 | |
| Profit/Loss From Continuing Operations | 48.45 | 46.16 | 56.82 | 34.94 | 24.83 | |
| Profit/Loss For The Period | 48.45 | 46.16 | 56.82 | 34.94 | 24.83 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 9.79 | 10.57 | 13.04 | 8.08 | 5.74 | |
| Diluted EPS (Rs.) | 9.79 | 9.29 | 11.45 | 7.09 | 5.04 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 18.99 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 3.23 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 38.00 | 0.00 | 0.00 | 0.00 | 0.00 |
28.10.2025
Thyrocare Techn Consolidated September 2025 Net Sales at Rs 216.53 crore, up 22.09% Y-o-Y
24.10.2025
15.10.2025
Thyrocare Techn Consolidated September 2025 Net Sales at Rs 216.53 crore, up 22.09% Y-o-Y
15.10.2025
Thyrocare Techn Standalone September 2025 Net Sales at Rs 202.23 crore, up 24.03% Y-o-Y
28.10.2025
Thyrocare Techn Consolidated September 2025 Net Sales at Rs 216.53 crore, up 22.09% Y-o-Y
15.10.2025
Thyrocare Techn Consolidated September 2025 Net Sales at Rs 216.53 crore, up 22.09% Y-o-Y
15.10.2025
Thyrocare Techn Standalone September 2025 Net Sales at Rs 202.23 crore, up 24.03% Y-o-Y
24.07.2025
Thyrocare Techn Standalone June 2025 Net Sales at Rs 178.89 crore, up 24.55% Y-o-Y
06.10.2021
Thyrocare Technologies Q2 PAT may dip 2.9% YoY to Rs 41.8 cr: Prabhudas Lilladher
12.07.2019
Thyrocare Technologies Q1 PAT may dip 6.5% YoY to Rs. 22.1 cr: Prabhudas Lilladher
12.04.2019
Thyrocare Technologies Q4 PAT seen up 18.1% YoY to Rs. 29.7 cr: Prabhudas Lilladher
17.04.2018
Thyrocare Technologies Q4 PAT seen up 68.7% YoY to Rs 32 cr: Edelweiss